• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Vertex Pharmaceuticals (VRTX)

Common Shares
Sell: $418.76|Buy: $420.40|Change: 2.29 (0.55%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Address

50 Northern Avenue
Boston
MA
USA
02210

Telephone

+1 617 9617163

Website

https://www.vrtx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Vertex Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-08-04T16:30:00
Vertex Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-08-04T00:00:00
Vertex Pharmaceuticals Inc Annual General Meeting for 20262026-05-14T09:00:00
Vertex Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-05T16:30:00
Vertex Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-05T00:00:00
Vertex Pharmaceuticals Inc Annual Report for 20252026-02-13T00:00:00
Vertex Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-02-10T16:30:00
Vertex Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252026-02-10T00:00:00
Investor Event at the American Society of Nephrology Kidney Week 20252025-11-08T20:00:00
Vertex Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-03T16:30:00
Vertex Pharmaceuticals Inc Third Quarter Earnings Result for 20252025-11-03T00:00:00

Previous key dates

NameKey Date
Bank of America Global Healthcare Conference2025-09-23T07:10:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-09T11:30:00
2025 Wells Fargo Healthcare Conference2025-09-03T11:00:00
Vertex Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-08-04T16:30:00
Vertex Pharmaceuticals Inc Second Quarter Earnings Result for 20252025-08-04T00:00:00
Investor Event on zimislecel (VX-880) at the American Diabetes Association 85th Scientific Sessions2025-06-20T19:15:00
Vertex Pharmaceuticals Goldman Sachs 46th Annual Global Healthcare Conference 20252025-06-10T14:40:00
Bernstein 41st Annual Strategic Decisions Conference2025-05-30T08:00:00
Vertex Pharmaceuticals Inc Annual General Meeting for 20252025-05-14T09:00:00
Vertex Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-05T16:30:00
Vertex Pharmaceuticals Inc First Quarter Earnings Results for 20252025-05-05T00:00:00
Vertex Pharmaceuticals Inc Annual Report for 20242025-02-13T00:00:00
Vertex Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-02-10T16:30:00
Vertex Pharmaceuticals Inc Fourth Quarter Earnings Result for 20242025-02-10T00:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-13T10:30:00
Suzetrigine Phase 2 Results in Lumbosacral Radiculopathy (LSR) Conference Call2024-12-19T08:00:00
Vertex Stifel Healthcare Conference 20242024-11-19T08:00:00
Vertex Guggenheim Inaugural Healthcare Innovation Conference 20242024-11-12T09:00:00
Vertex Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-11-04T16:30:00
Vertex Pharmaceuticals Inc Third Quarter Earnings Result for 20242024-11-04T00:00:00
Investor Event on Suzetrigine (VX-548) at the American Society of Anesthesiologists' Meeting2024-10-20T18:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.